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Abstract
Background: Viscum album L extracts (VAE, mistletoe) and isolated mistletoe lectins (ML) have immunostimulating
properties and a strong dose-dependent cytotoxic activity. They are frequently used in complementary cancer
treatment, mainly to improve quality of life, but partly also to influence tumour growth, especially by injecting VAE
locally and in high dosage. The question is raised whether these higher dosages can induce any harm or
immunosuppressive effects.
Methods: Systematic review of all experiments and clinical studies investigating higher dosages of VAE in animals
and humans (Viscum album > 1 mg in humans corresponding to > 0.02 mg/kg in animals or ML > 1 ng/kg) and
assessing immune parameters or infections or adverse drug reactions.
Results: 69 clinical studies and 48 animal experiments reported application of higher doses of VAE or ML and had
assessed immune changes and/or harm. In these studies, Viscum album was applied in dosages up to 1500 mg in
humans and 1400 mg/kg in animals, ML was applied up to 6.4 μg/kg in humans and in animals up to 14 μg/kg
subcutaneously, 50 μg/kg nasally and 500 μg/kg orally. A variety of immune parameters showed fluctuating or
rising outcomes, but no immunosuppressive effect. Side effects consisted mainly of dose-dependent flu-like
symptoms (FLS), fever, local reactions at the injection site and various mild unspecific effects. Occasionally, allergic
reactions were reported. After application of high doses of recombinant ML, reversible hepatotoxicity was observed
in some cases.
Conclusions: Application of higher dosages of VAE or ML is not accompanied by immunosuppression; altogether
VAE seems to exhibit low risk but should be monitored by clinicians when applied in high dosages.
Background
Complementary cancer treatment is utilised by 15-73%
of all cancer patients in Europe, in addition to well
established oncological treatments [1]. Most of these
complementary treatments are herbal remedies and
among these, Viscum album L extracts (VAE, European
mistletoe, a hemiparasitic shrub, not to be confused
with the Phoradendron species or “American mistletoe”)
are frequently used [1]. Physicians in Germany consider
VAE to have a relevant therapeutic benefit [2].
VAE contains a variety of biologically active com-
pounds. Of these, mistletoe lectins (ML I, II and III)
have been most thoroughly investigated. ML consist of
two polypeptide chains: a carbohydrate-binding B-chain
that can bind to cell surface receptors and thus enable
the protein to enter the cell [3-5]; and the catalytic A-
chain which can subsequently inhibit protein synthesis,
due to its ribosome-inactivating properties, by removing
an adenine residue from the 28S RNA of the 60S subu-
nit of the ribosome [3]. Other pharmacologically rele-
vant VAE compounds are viscotoxins and other low
molecular proteins, VisalbCBA (Viscum album chitin-
binding agglutinin) [6], oligo- and polysaccharides [7,8],
flavonoids [9], vesicles [10], triterpene acids [11], and
others [12,13].
Whole VAE as well as several of the compounds are
cytotoxic and the ML in particular have strong apopto-
sis-inducing effects [14-16] and also stimulate the
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cytes/macrophages, granulocytes, natural killer (NK)
cells, T-cells, dendritic cells, induction of a variety of
cytokines) [12,13].
For clinical application, VAE are made from mistletoe
grown on different host trees (table 1). Depending on
t h eh o s tt r e e ,t h eh a r v e s t i n gt i m ea n dt h ee x t r a c t i o n
procedure, VAE vary in regard to their active com-
pounds and biological properties. Different commercial
VAE preparations are available, and a recombinant ML
(rML) drug is currently being developed and tested in
animals [17-19] and in clinical trials [20-22].
Effectiveness and efficacy of VAE have been assessed
in various systematic reviews [23-30]. Safety aspects,
besides being secondary outcomes in these reviews,
were assessed systematically in five specific reviews: two
on adverse reactions [31,32], one on toxicology [33], and
one each in a health technology assessment (HTA)
report [34] and in a comprehensive review on VAE
research [35].
In cancer therapy, VAE are usually applied at a rather
low dosage, adjusted individually according to local
reactions at the injection site (LR) and individual toler-
ability. Increasingly, however, VAE are also applied in
high dosages, either intratumourally, systemically (sub-
cutaneously), or as an intravenous infusion to achieve
tumour remission or to substantially improve quality of
life [36-40].
As VAE not only have immunostimulatory but also
cytotoxic properties - some of its components, like the
ML, are highly cytotoxic, comparable to conventional
cytotoxic agents [41-45] - the question is raised whether
VAE in high dosage can lead to severe side effects and,
specifically, whether they suppress immune functions,
which is a well-known detrimental effect of other cyto-
toxic anticancer drugs. This question was raised in a
casuistic report achieving tumour remission with high
dosage VAE infusion (up to 700 mg Helixor) [46] and
in an animal experiment applying 2.5 and 5 ng ML I/kg
body weight (BW) in mice [47].
Tolerability of high dosage VAE has not yet been
assessed systematically in any of the above mentioned
reviews, especially not the question of immunosuppres-
sion. Still, in a variety of animal experiments and clinical
studies, high doses of VAE or ML have been applied
and haematological, immunological and general safety
outcomes assessed. We decided to systematically review
these clinical studies and animal experiments to assess
the following questions: Do VAE or ML have immuno-
suppressive effects when they are applied at higher ther-
apeutic dosages? Which other side effects have been
observed in studies or experiments when VAE or ML
are applied at higher dosages? Are these dose-depen-
dent? - Purely toxicologic tests were not reviewed, as
they have already been reviewed elsewhere [33]. Also,
these tests employ ultrahigh and lethal dosages to pro-
voke toxic effects, which are not used therapeutically;
their review would require a different methodology and
would have to cover other material as well (e.g. in vitro
tests).
As VAE-induced immunostimulation is observed in
low dosages of 1 mg Viscum album and 1 ng ML/kg
BW, which is generally considered to be an immunosti-
mulating dosage, we set these dosages as a threshold for
“higher dosage”, although this is somewhat arbitrary.
Methods
Design
Systematic review of clinical studies and animal experi-
ments. Methodology and presentation adhere to
PRISMA guidelines [48] and to recommendations for
conducting systematic reviews of adverse effects [49].
Identification of secondary immunosuppression
Immunosuppression is one category of immunotoxic
effects - encompassing also hypersensitivity, autoim-
munity and adverse immunostimulation [50,51].
Immunosuppression refers to a profound impairment
of the immune response leading to an increased sus-
ceptibility to infectious micro-organisms, partly with a
specific viral or bacterial spectrum depending on the
type of immune defect, and to more frequent neopla-
sias, in particular lymphomas [50,52]. Secondary
immune defects - far more common than primary
immunodeficiencies, resulting from inborn genetic
defects - are caused by a var i e t yo ff a c t o r sl i k ed r u g s
(e.g. anticancer cytotoxic agents, corticesteroids, some
antibiotics), radiation, and various illnesses (HIV-infec-
tion, malignant or metabolic diseases, protein-losing
syndrome, severe malnutrition, polytrauma, excessive
physical stress) [50,53].
Table 1 Host trees of Viscum album, used in medical
preparations
Fir Abies (A)
Maple Acer (Ac)
Almond Amygdalus (Am)
Birch Betula (B)
Hawthorn Crataegus (C)
Ash Fraxinus (F)
Apple Malus (M)
Pine Pinus (P)
Poplar Populus (Po)
Oak Quercus (Qu)
Willow Salix (S)
Lime Tilia (T)
Elm Ulmus (U)
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approach is generally recommended. The first step con-
sists of observations from clinical or standard non-clini-
cal toxicology studies, leading to the suspicion of
immunosuppression: i.e. increased infections, increased
incidence of neoplasias, abnormal results of complete
and differential blood count (CBC and DBC) or serum
immunoglobulins. An optional or second step would
assess delayed type hypersensitivity (DTH), and, in case
of standard toxicological studies, weight and histology of
immune organs. If these are clearly abnormal, further
specific immunological tests are recommended [54].
A detailed algorithmic screening was proposed as
follows [55]. Step 1: Anamnesis (increased susceptibil-
ity to infections, at least 3 periods of infections per
year, each of more than four weeks duration [56]),
CBC, DBC, and quantitative determination of immuno-
globulins. If findings are abnormal, step 2: T-cells, thy-
mus size, DTH, T-cell phenotyping, lymphocyte
transformation test. If findings are abnormal, step 3: B-
cells, IgG subclasses in case of IgA deficiency, isohae-
magglutinin, immunisation. Subsequently step 4: com-
plement, phagocytic activity. And, when indicated, step
5: molecular biological testing. If no clinical symptoms
or clear pathological alteration of these immune para-
meters are present, further elaborate analyses of
immune functions are of questionable use and may be
misleading [55-58].
Fluctuating immune parameters are normal to a large
extent [54,59]. Furthermore, transient, short-term
changes of immune parameters connected to acute
stress, including application of very high doses of phar-
maceuticals, are well-known; they are not correlated to
subsequent immunosuppression but to immunostimula-
tion [60,61]. (See also discussion section.)
According to the above mentioned recommendations
we screened clinical and animal studies with regard to
whether clinical signs or a clear and consistent patholo-
gical alteration of classical immune parameters were
observed during higher doses of VAE or ML.
Identification of adverse drug reactions (ADRs)
An adverse drug reaction is an untoward event present-
ing during drug treatment at doses normally used in
humans and for which a causal relationship between the
drug and the event is at least ar e a s o n a b l ep o s s i b i l i t y ,
according to the judgement of the reporting or review-
ing health care professional. For this review we screened
all trials, studies, case-series and animal experiments
applying higher dosages for reports of ADRs (e.g. “side
effects”, “adverse events”, “adverse effects”, “adverse
reactions”, “ADR”, “toxicity”, “safety”, “tolerability”,
“laboratory changes”, “abnormalities”, “systemic symp-
toms”). Causal relationship was not additionally assessed
if this was already done by the reporting health care
professional.
Search strategy
We used a systematic process to search eight databases
for clinical studies and animal experiments - from
inception of these databases to February 2011. For
details (databases, search terms, search strategies,
results) see Additional file 1: Literature Search.T h e
reference list from each potentially eligible study, rele-
vant review article and textbook was checked, and
experts in the field and manufacturers of mistletoe pre-
parations were contacted for additional reports.
As no single index or subheading search term reliably
identifies data on adverse effects or immunosuppression
[49], all trials, clinical studies, case series, and animal
experiments were individually checked for inclusion cri-
teria. They were screened by two independent research-
ers (GSK, RG) for identification of eligibility criteria,
especially applied dosage and whether ADRs were
reported or immune parameters or episodes of infec-
tions were assessed. The study selection process is pre-
sented in Figure 1.
Eligibility criteria
The following selection criter i aw e r eu s e df o ri n c l u s i o n
of studies in the analysis: (I) clinical study (prospective
randomised controlled trial, RCT, or non-randomised
controlled study, or prospective single-arm cohort study,
or phase II trial, or case series) or animal experiment;
(II) study population with any disease or without dis-
eases; (III) intervention group treated with VAE pre-
paration dosed at > 1 mg Viscum album, corresponding
to 0.02 mg/kg BW in animals, or > 1 ng ML content/kg
BW or with isolated or recombinant ML dosed at > 1
ng/kg BW; (IV) outcome measure: immune parameter
(i.e. white blood cells, lymphocytes, granulocytes, immu-
noglobulins, complement factors, cytokines, cellular or
humoral immune response, weight and histology of
immune organs; studies only presenting anti-ML antibo-
dies were not included) or ADRs; (V) completion of
study or interim report; (VI) published or unpublished.
There were no restrictions on language. For animal
experiments, unpublished material was not included.
Purely toxicologic tests were not included (for review
see [33]).
Validity assessment and data abstraction
As we are conducting a widely scoped review [49] and
also because we are searching for rare effects [49] and
for effects present under higher dosage and alternative
application forms which are investigated mainly in sin-
gle-arm studies and animal experiments, we included
different kinds of clinical studies, irrespective of their
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experiments. Study design, detecting methods and
reporting quality play a key role concerning the risk of
bias when side effects are investigated in clinical or ani-
mal studies; beyond this, however, there is no validated,
reliable quality assessment tool for the analysis of
adverse effects [49]. We therefore critically discussed
and appraised all studies individually. They were classi-
fied according to design, especially pertaining to
whether they compared the outcome to a control group
or to the status before intervention; whether the alloca-
tion of the intervention had been randomised; whether
the treatment application had been blinded; and whether
participants were healthy or not. Methods used to detect
immune changes or adverse effects were assessed as well
as the duration of follow-up, co-interventions potentially
influencing the outcomes, reporting of results as well as
general study characteristics: whether they were prone
to bias, inflating or deflating potential side effects, drop
outs and general publication quality. Corresponding
results were presented when they had an influence on
the outcome of interest (for other outcomes, see
[23-26]).
Data on participants, intervention, co-intervention,
detecting methods, and outcomes referring to safety and
the immune system (except anti-ML-antibodies) were
abstracted in evidence tables by one researcher and
checked by a second (GSK, RG). ML content of VAE
was obtained from the respective publication, or, if not
available, it was either left out, or calculated from other
contemporary publications on the same preparation, or
calculated on the basis of information provided by the
corresponding manufacturer. This latter information is
based on average values from different batches and
includes a degree of fluctuation. One has to be aware
that, firstly, the dosages of different preparations cannot
be compared, due to different extraction procedures;
that, secondly, the ML content of different preparations
cannot be compared as they are measured with different
assays (e.g. ELLA, ELISA [62]) and have different pro-
portions of ML I and ML II/III; and that, lastly, lectins
are only part of the oncologically active ingredients of
VAE. The indication of the lectin content shall only
serve as an approximate orientation, and does not claim
precision nor sole clinical relevance. This is particularly
the case for quantification of ML dosages in older
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Figure 1 Literature search and study selection.
Kienle et al. BMC Complementary and Alternative Medicine 2011, 11:72
http://www.biomedcentral.com/1472-6882/11/72
Page 4 of 15studies (before ~ 1990) which often used different, non-
standardised methods and therefore do not allow
comparison.
Besides the included studies, also all excluded studies
were screened for major adverse events. As the studies
have a high heterogeneity in regard to design, compari-
son group, modalities of therapy, assessment of immune
changes and ADRs, analysis, and reporting, we consid-
ered that a quantification of results, e.g. relative risk,
would be highly imprecise and misleading. Therefore
the information was summarised in a qualitative and
descriptive manner in tables and in the text.
Results
Clinical studies - selection and characteristics
Regarding literature search and study selection see Fig-
ure 1 and Additional file 1. Altogether, 69 clinical stu-
dies matched inclusion criteria. Their characteristics are
summarised in table 2 and their details are presented in
Additional file 2. The methodological quality of the stu-
dies varied substantially (see table 2 and Additional file
2, for further quality aspects of the clinical studies, see
[12,24-26]). 10 of the studies were conducted following
modern standards of good clinical practice.T h ei m m u -
nological and safety outcomes of the studies were pre-
sented only partly numerically and in detail; often they
were summarised, just mentioned in the conclusion sec-
tion or the abstract or not reported. Missing patients
were often not reported for immunological or toxicity
outcome.
Clinical studies - immunological results (see Additional
file 2)
Most studies reported an increase of the immune para-
meters during or after VAE/ML application, some
reported no significant difference and some a decrease.
In detail:
Infections: A dose-dependent (maximum 5 mg)
increase of episodes was observed in HIV positive
patients [63,64], however without being accompanied by
a deterioration of immune parameters and therefore
without any signs of immunosuppression. All other stu-
dies showed a decreased incidence and duration of
infections - respiratory infections in immunosuppressed
children (due to the Chernobyl nuclear accident) [65],
or common colds in healthy subjects [66,67].
Haematology (leukocytes): One study applying escalat-
ing doses of recombinant ML - up to 6400 ng/kg -
observed a slight and transient leukocytopenia (common
toxicity criteria, NCI CTC, grade 1) during the first
cycle in four of the 41 patients with advanced, refractory
progressive cancer [20]. In subsequent treatment cycles
as well as in a subsequent study, the same recombinant
ML was applied in the same dosage, but no
leukocytopenia and no other haematological toxicity
were observed [20,21]. In two other studies (without a
control group), one described a slight, transient, non-
significant decrease of leukocytes after month 6 in can-
cer patients (to an average of 5281 cells/μl, standard
deviation: 1145) [68], the other described a decrease of
leukocytes (to a minimum of 5500 cells/μl) in patients
with a prior leukocytosis (and, vice versa, an increase of
leukocytes after prior leukopenia) [69]. All other studies
showed either an increase, or no difference or an
improved recovery from chemo- or radiotherapeutic
toxicity. So, no indication of haematologic toxicity or
granulocytopenia was observed.
Lymphocytes: A reduction was described in some of
the studies: In one study lymphocytes decreased (to a
minimum of 3500 cells/μl, standard error: 340) in
patients with an initial leukocytosis, while patients with
initially low values showed rising lymphocytes [70]. In
other studies either a reduction of lymphocytes within
normal range or an initial, transient reduction after
starting VAE treatment was mentioned. In one com-
parative study, reduced lymphocytes were observed in
patients applying VAE concomitantly to chemotherapy,
especially when the patients had additional glucocorti-
coids; here, groups were not easily comparable; they
particularly differed with regard to co-therapy, and no
adjustment was made for patients’ imbalances [71]. Two
further studies found a reduction of CD8 cells (inter-
preted as suppressor cells), while other lymphocyte sub-
sets increased [72-74]. Finally, one study found a slight
decrease of the proportion of CD3+T-cells expressing
CD25 after mitogen (PHA) stimulation ("activated” T-
cells) during 6 months of VAE treatment in cancer
patients; the patients were treated either by a physician
preferring a slow or by another physician preferring a
swift VAE dosage escalation, and the respective decrease
was more pronounced during the swift dose escalation
("swift” group: from 80.8 to 74.4%; “slow” group: from
74.6 to 69.9%), but did not depend on the dosage actu-
ally applied. These decreases were, however, still within
the range of healthy controls (72.9%). Besides, the pro-
portion of HLA-DR+CD3+ T-cells decreased in the
“swift” group but not in the “slow” escalation group [75].
Immunoglobulins: An increase was observed in two
studies [65,74]; specific anti-ML-antibody production
was assessed in 10 of the reviewed studies (data not
shown).
Cytokines: The studies showed highly variable results,
with mostly increase, but also decrease of the corre-
sponding cytokine endpoint, without any indication for
immunosuppression.
Remaining parameters - functional capacity of granu-
locytes, NK-cell number and activity, peritumoural and
tumour infiltration, VAE- or mitogen-induced
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mononuclear cells, complement factors, acute phase pro-
teins, ADCC: The studies found either an increase or no
significant change, or an initial transient decrease (NK
and ADCC activity) in one study [76,77].
Altogether in these 57 studies no indication for an
immunosuppression through VAE or ML was found,
not even when high doses of VAE or ML were applied.
Especially the studies that compared outcomes to a con-
trol group found no immunosuppressive effects.
Clinical studies - ADRs (see Additional file 2)
Of the 58 studies mentioning safety assessment during
VAE application, two did not report any results; 32 stu-
dies reported to have observed no ADRs, to have good
tolerability or mainly LR; 20 studies reported to have
observed well-known or unspecific and usually mild side
effects or events with unclear relation to VAE applica-
tion, like rise in temperature, fever, FLS, mild infections
(see above), headache, lassitude, fatigue, dry eyes, flatu-
lence/loose stool, nausea, moderate pain after intraperi-
toneal or intrapleural instillation, cutaneous rash,
anxiety during sleep or slight changes of laboratory
parameters within the normal range (see below). Of the
remaining 4 studies, besides reporting good tolerability,
one also reported grade 3 cellulitis, two studies an
angioedema/urticaria occurring in two patients [78,79] -
Table 2 Characteristics of the clinical studies (n = 69)
Number of
studies
Types of study
Controlled studies, comparing outcome to
control group (2912 patients included)
25
Randomized 22
Double blind 6
Single blind 1
Single-arm studies, comparing outcome
pre-post
(1347 patients included)
44
Diagnoses
Healthy participants 10
Cancer 48
Others: Hepatitis C, immunosuppression, HIV infection,
osteoarthritis, anal condyloma (4 × mixed: HIV &
healthy; 1 × mixed: HIV & healthy & cancer)
11
Treatment
Whole extract 66
Recombinant ML 3
Application route
Subcutan, intracutan 50
Intravenous * 10
Intrapleural, intraperitoneal, intravesical * 7
Intratumoural * 2
Application frequency
Applied just once 7
Applied more than once in constant dosage
(up to 3 years)
12
Applied more than once in escalating dosage
(up to 6 years)
50
Maximum dose per application
≤ 20 mg VAE 36
> 20 - 100 mg VAE 15
> 100 mg VAE (maximum dose: 1500 mg; maximum
ML content: 45000 systemically, 250000 ng
intravesically)
15
> 100000 ng rML (maximum dose: 448000 ng) 2
< 100000 ng rML 1
Observation time < 1 month 14
Treatment of control group (n = 25)
No additional treatment 14
Placebo 6
Active (multivitamins, Lentinan, Etoposide, BCG,
non-stimulating skin control test/immignost)
5
Immune outcomes investigated 57
Clinical infections 4
Peripheral blood: CBC, DBC, lymphocytes & subsets,
mitogen-induced proliferation, cytokine release,
NK-cells & activity, ADCC, phagocytosis of
granulocytes, cytokines; immunoglobulins, CRP,
haptoglobin, others
55
Immune parameters in tumour tissue, pleural
effusion, saliva, urine
6
Table 2 Characteristics of the clinical studies (n = 69)
(Continued)
Safety outcomes investigated 61
Safety as primary objective of the study 6
Systematic and regular assessment of clinical and
laboratory parameter (electrolytes, urea, AST, ALT, g-GT,
AP, bilirubin, creatinine, creatine kinase, LDH, protein,
albumin, glucose, cholesterol, triglycerides, a-amylase)
29
Recorded according to NCI CTC, WHO toxicity criteria,
Likert scale, Lilly tables
17
Other modalities of recording 16
No details on recording 16
Time schedule of safety assessment
Daily (e.g. diary) 6
Weekly, biweekly 12
Monthly, every 3 weeks 13
Quarterly 4
Once 2
„Regular” 7
No details or no systematic plan 25
* Partly concomitant sc application
Abbreviations: ADCC: antibody-dependent-cell-mediated cytotoxicity, ALT:
Alanine transaminase, AP: alkaline phosphatase, AST: aspartate transaminase,
CBC complete blood count, CRP: C-reactive protein, DBC: differential blood
count, g-GT: g-glutamyltransferase, LDH: lactate dehydrogenase, NCI CTC:
National Cancer Institute - Common Toxicity Criteria
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was no longer observed when dosage was reduced [79] -
and one study also short-term ADRs in three patients
(after intraperitoneal application of high doses of VAE)
which were not specified [80]. Of the studies referring
to laboratory parameters, two described a slight increase
of urea and creatinine, and a slight decrease of albumin,
haemoglobin and erythrocytes (HIV positive patients) -
a l lw i t h i nn o r m a lr a n g e s-d u r i n gs e v e r a lm o n t h so f
VAE application [63,64]. All other studies reported no
deviations and particularly no organ toxicity.
Three phase I trials investigated the dose-limiting
toxicity of an experimental compound, a recombinant
ML (rML) preparation in patients with advanced cancer
(with no control group to distinguish from disease
symptoms or else). rML was applied as a 1 h or a 24 h
central intravenous infusion in two studies, with dose
levels ranging from 10 to 6400 ng/kg and from 4000 to
6000 ng/kg [20,21], and as an subcutaneous injection up
to 10 ng/kg in the third trial [22]. rML was reported as
being very well tolerated in all three studies. Most fre-
quently observed were LR, fatigue, fever, nausea, vomit-
ing, and high urinary frequency, usually grade 1-2. At
6000 and 6400 ng/kg, dose-limiting toxicity occurred
with reversible grade 3 liver toxicity (increase of AST,
ALT, AP, or g-GT), hypokalaemia and fatigue in alto-
gether five patients (one of these also at a rML-dose of
4.8 μg/kg) [20,21]. After the first injection of 5000 ng/kg
rML, two VAE pre-exposed patients had an anaphylactic
reaction with generalized urticaria; one of them also
with dysphagia and swelling of the larynx [21]. Further
grade 1-2 events included chills, diarrhoea and constipa-
tion, arthralgia, chest pain, tumour pain, headache, diz-
ziness, flushing, itching, hypotension, anorexia, sweating,
insomnia, mouth dryness, sensory neuropathy, taste dis-
turbance [20-22]. One further grade 3 event was hyper-
tension, occurring in 1 patient [22]. Further laboratory
abnormalities documented during study period - it was
unclear whether they were related to rML treatment or
to advanced cancer disease or to other causes - were
mostly grade 1-2, including thrombopenia (grade 1),
anaemia, hypoalbuminaemia, hypoproteinaemia, hypo-
and hypercalcaemia, hypo- and hypernatraemia, hypoka-
laemia, hyperbilirubinaemia, slight increase of creatinine
[20-22].
Most of the ADRs or adverse events were reported
from studies with no control group (37 studies, see
Additional file 2), which impedes the discrimination of
ADRs from underlying disease symptoms or sponta-
neously occurring events and therefore increases the
risk of false positive findings; only part of these studies
assessed causal relation with VAE or rML treatment. Of
the 24 studies comparing outcome with a control group
(see Additional file 2) and thus reducing the risk of bias,
tolerability was usually good, without ADRs, except an
angioedema/urticaria in one case, frequent LR (16 stu-
dies), fever, rise in temperature or FLS (5 studies), or
individual cases of dry eyes, flatulence/loose stool and a
“general vegetative reaction”.
Altogether, most frequently reported ARDs in the stu-
dies were LR, i.e. erythema, induration, swelling, warmth
and sometimes pain at the injection site; they were
dose-dependent, self-limited and appeared less intensely
and less frequently after some weeks of treatment. His-
tological investigation showed a superficial and deep,
dense lymphoid infiltration in corium and subcutaneous
fat: 60% T-cells (half CD4 and CD8 cells) and 40%
macrophages. After intravenous infusion of VAE or rML
in VAE-pre-exposed patients, LR sometimes appear at
former injection sites. Also frequent, particularly after
very high dosage, are FLS, fever, partly with chills, head-
ache, irritation of the gastrointestinal system, pain (espe-
cially after intrapleural or intraperitoneal application),
fatigue/dizziness or lassitude. Single, infrequent observa-
tions had been reversible liver toxicity (see above), mild
infections and allergic reactions. The other reported
ADRs were restricted to individual cases or to studies
without comparison groups and without a clear dose-
dependency or other observations to clearly distinguish
the events from symptoms of underlying diseases.
Animal experiments - characteristics
Regarding literature search and study selection see
Figure 1 and Additional file 1. Altogether, 48 animal
experiments or experimental settings matched inclusion
criteria. Their characteristics are summarised in table 3
and details presented in Additional file 3. The quality of
the experiments and their reporting, especially regarding
immune outcomes and safety, varied substantially.
Often, experiments consisted of several sub-experiments
with safety results usually reported globally; accordingly,
these sub-experiments are summarized in this review as
well.
Animal experiments - immunological results (see
Additional file 3)
Most animal studies reported an increase or no change
of the measured immune parameters and some a
decrease of certain parameters.
Incidence and duration of infections were not mea-
sured in the reviewed studies.
Haematology: One study described a decrease of the
relative amount of neutrophils and monocytes, 24 hours
after single application of VAE (5 mg/kg), and a relative
increase of lymphocytes. These were interpreted as
immunostimulatory, however, no absolute counts were
reported [81]. All other experiments observed no leuko-
penia or haematological toxicity or significant decrease
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difference to the control group, also after application of
higher doses of VAE. Endoxan-, radiation- or dexa-
methasone (DX)-induced leukopenia was reduced by
VAE.
Unspecific serum immunoglobulins: One study assessed
serum proteins - total proteins, albumin, globulins a2, b
and g, composed by a multitude of different proteins -
24 hours after a single injection of VAE (5 mg/kg) and
found lower levels of total proteins and the globulins
than in a control group [81].
Humoral or cellular immune response against foreign
antigens (immune function tests): All ten experiments
showed a substantial enhancement of the immune
response, but two also found varying results: In one
study - insufficiently described - VAE was applied daily
in three dosages (Isorel 14 or 140 or 1400 mg/kg) over
1 or 14 or 25 days in mice before or concomitant to
immunisation with sheep red blood cells (SRBC),
assessed by the plaque-forming cell (PFC) assay. The
results varied substantially between all groups, also
between the three placebo (control) groups, associated
with a large standard deviation; most results showed an
increase of PFC after VAE application, except a decrease
after application of VAE over 5 weeks (25 injections),
especially in lower dosage; this decrease had a similar
magnitude as the variation between the three control
groups, where PFC increased fivefold (and standard
deviation more than thirtyfold) with repeated applica-
t i o n so fs a l i n e ;t h ec u m u l a t i v ed o s a g es h o w e dn od o s e -
response pattern [82,83]. In the other study, VAE was
given during 3 days either before or 6 days after the
injection of SRBC in mice, and an either reduced or
increased antibody titer was observed (day 10), respec-
tively; the dose was comparatively low [84]. (Another
similar experiment found an increased antibody forma-
tion when VAE was applied before, and no change
when it was given after SRBC [85].) All other 8 experi-
ments showed a substantial increase of humoral
Table 3 Characteristics of the animal experiments (n =
48)
Number of
studies
Animals
Mice 42
Rats (1 × mixed: rats & mice) 4
Horses, Cats 2
Diagnoses
Healthy animals 21
Cancer * (2 × mixed) 27
Treatment
Whole extract 34
Isolated or recombinant ML 14
Application route
Subcutan, intraperitoneal ** 35
Intratumoural, intravenous, intramuscular, intracutan,
oral, intranasal, intravesical
13
Application frequency
Applied just once 10
Applied more than once (5 × mixed) (up to several
months)
38
Maximum dose per application
≤ 20 mg mg/kg VAE 12
> 20-100 mg/kg VAE 16
> 100 mg/kg VAE (maximum dose: 1400 mg/kg) 6
> 50 ng/kg ML (maximum dose: 500 μg/kg oral, 50
μg/kg intranasal, 14 μg/kg sc)
9
< 50 ng/kg ML 5
Observation time < 1 week 6
Treatment of control group
Placebo 33
No additional treatment or unclear 14
No control group 1
Immune outcomes investigated 38
Peripheral blood: CBC, DBC, leukocytes, lymphocytes,
monocytes, granulocytes, T-cell subsets, activation
markers, TNF-a
14
Immunoglobulins/humoral response to foreign
antigens
9
Cellular response to foreign antigens, foreign skin graft
rejection
2
Thymus (size, histological analysis, thymocytes, subsets,
function
14
Spleen (size, weight, morphometric analysis,
splenocytes, subsets, function)
8
Lymph nodes (weight, morphometric analysis) 2
Peritoneal macrophages and activity 3
Influence on leukopenia caused by radiation,
chemotherapy, dexamethasone.
4
Others (tumour tissue, urinary bladder tissue,
bronchoalveolar lavage)
4
Safety outcomes investigated 17
Monitored for toxicity, tolerability, vitality, clinical signs,
body weight, food/water consumption, behavior,
physical responses of the animals, local effects
9
Table 3 Characteristics of the animal experiments (n =
48) (Continued)
Necropsy 2
Bladder histology after intravesical instillation of VAE 1
No details on recording 8
Time schedule of safety assessment
Daily, 2/week 5
„Regular” 1
No details or no systematic plan 11
* therapeutic application of VAE in 2 studies: equine sarcoid in horses [92],
fibrosarcoma in cats [93];
** Injection of tumour cells that had been pre-incubated with VAE or ML in 2
studies [98,99]
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response after antigen stimulation in combination with
VAE or ML, partly applied in very high doses [86-90].
Immune organs: Size and weight of thymus and spleen
mostly increased and sometimes did not change; histol-
ogy showed a hyperplasia of the thymus cortex and a
proliferation of lymphoid cells in spleen and lymph
nodes. Number and function (mitogen stimulated prolif-
eration, secretion of cytokines, NK-cytotoxicity, ADCC)
of splenocytes and thymocytes and their subsets also
increased or stayed unchanged after application of VAE
or ML (sometimes in high dosage), except in one study
that found, 48 hours after injection of 30 ng/kg recom-
binant ML I, a decrease of splenocytes’ NK-cytotoxicity
(and of the number of circulating LGLs), while they
increased after injection of 0.5 or 1 ng/kg rML and
stayed unchanged after 3 and 10 ng/kg; also lympho-
cytes increased, while polymorphonuclear leukocyte and
lymphocyte subsets showed no change [91].
Lymphocytes showed increased levels in the peripheral
blood after VAE or ML application.
Remaining immune parameters - i.e. number or cyto-
toxicity of peritoneal macrophages, macrophages in
bronchoalveolar lavage: The studies showed no depres-
sion but either increase or no change.
Altogether, no immunosuppression caused by VAE or
ML was found in any of the studies, not even when
high dosages of VAE of ML were applied.
Animal experiments - ADRs (see Additional file 3)
Ten of the 17 studies, including the two therapeutic
trials [92,93], reported good tolerability and no ADRs
except mild edema at the injection site in a RCT on
horses. One study reported weight loss at 50 mg/kg of a
lectin-rich VAE preparation, good tolerability and no
toxicity of the other VAE preparation up to 100 mg/kg
[94]; one further study reported local intolerance after
intravesical application of high doses of VAE (12000 ng
ML/kg) [95]. Altogether five studies observed increasing
toxicity and lethality when applying very high doses
[42,96-99], close to or higher than LD50 (median lethal
dose) [12,33,98,99] and far exceeding doses normally
used, so these lethal events are more a matter of poison-
ing [12].
Discussion
In the 69 clinical and 48 animal studies reviewed, asses-
sing a variety of immune parameters and ADRs, no indi-
cation for an immunosuppressive effect through higher
dose VAE or ML application was found. The studies
reported stable, fluctuating or increased immune out-
comes. Reported ADRs mainly consist of dose depen-
dent FLS, local reactions at the injection site, fever and
chills (especially under higher dose), also headache,
fatigue and mild gastrointestinal symptoms. In a few
cases, after intravenous infusion of very high doses of
recombinantly produced ML (4800 and 6400 ng/kg),
reversible hepatotoxicity and anaphylactic reactions were
observed. Angioedema/urticaria was also observed in 2
other patients [32,34], one of which occurred only after
the application of higher dosage VAE, and was no
longer observed after dose reduction. Of all animal
experiments five reported lethality after application of
very high doses [42,96-99], within the dosing range of
lethal doses [33,34], e.g. in an experiment published in
1987: 200 ng (10000 ng/kg) ML I given intraperitoneally
in mice [97].
These observations are in accordance with the
excluded studies which were also screened and which,
in general, showed good tolerability and comparable
ADRs. Also, previous analyses of ADRs and toxicity had
similar results: An HTA-report analysing all clinical stu-
dies on VAE and all case reports did not find organ
toxicity or biochemical changes, but frequent reporting
of self-limited, dose-dependent LR and FLS and the
occasional occurrence of allergic or pseudoallergic reac-
tions [34]. The latter are also described in published
case reports [32,34]. Additionally, one case of sarcoidosis
potentially induced by VAE has been published [100];
observational studies report a favourable outcome after
VAE application in sarcoidosis [101,102]. One review
asked health authorities for reported adverse events con-
nected to VAE treatment [31]; here, however, causal
relationship between the reported adverse events and
the VAE application had not been investigated and is
questionable, especially as in at least some cases the
adverse events are well-known symptoms of the under-
lying disease or the side effects of co-medications. Toxi-
cologic investigations were reviewed as well; no
indications for chronic toxicity were found [12,33]. Still,
mistletoe - perhaps influenced by its unfortunate reputa-
tion as “kiss of death” and having been misused for kill-
ing the god Baldur in Norse mythology - gave rise to a
number of reports in the popular and medical literature
on a variety of alleged harm. These, however, did not
h a v ea n yo ro n l yaf a u l t ye m p i r i c a lb a s i s[ 3 4 ] .A l s oa n
acute “mistletoe hepatitis” was reported to have
occurred after oral consumption of herbal tablets [103]
which, however, were subsequently shown not to have
contained any VAE [104]. In rats, VAE prevented acute
hepatic damage caused by carbon tetrachloride [105].
Regarding immune parameters, a few of the reviewed
studies reported decreases of outcomes. “Downs” of
immune parameters, however, do not necessarily docu-
ment an immunosuppression: Immune cells and mole-
cules fluctuate naturally in time and vary between
individuals. Also daily activities, diseases, the way of tak-
ing blood samples and its analysis have a major impact
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regression to the mean (decrease of initially high values,
increase of initially low values) have to be expected.
Furthermore, measurements from the peripheral blood
mirror only a secondary compartment of the immune
system as the relevant functions take place directly in
the lymphoid or tumour or inflamed tissue. Besides
their high turnover, immune cells fluctuate and only a
minor portion is in the peripheral blood - for instance
2% of lymphocytes, while 98% are in tissues. Redistribu-
tion of cells towards tissue with - transient - decrease in
the blood compartment is not indicative of immunosup-
pression [12,57,59,106-108]. Last but not least, the
immune system functions as a network with manifold
modifying, synergistic, antagonistic, redundant, context-
dependent interactions of the pluripotent, pleiotropic
and multifunctional cytokines and cells. Within this net-
work quantitative changes of single parameters have a
different meaning than within an isolating assay, and
their clinical interpretation is arbitrary to a large extent.
More important is therefore the performance of the
complete immune system - for instance susceptibility to
infectious disease or to cancer or functional tests, i.e.
immune response to foreign antigens - and in the case
of laboratory measurements, whether essential immune
parameters (CBC, DBC, immunoglobulins) can show a
clear pathological aberration.
In the reviewed studies, number and duration of infec-
tions decreased in immunocompromised children as
well as in healthy subjects but showed an increase in
HIV positive patients: transient exacerbations of gingivi-
tis, candidiasis, FLS, sinusitis and herpes simplex in a
clearly dose-dependent manner [63,64]. This increase,
however, was neither due to disease progression, nor
accompanied by suppression of immune parameters
[63,64,109] and may have been caused by an increase of
the inflammatory response due to immunostimulation
through VAE. Nevertheless, these observations should
be investigated in more detail. Furthermore, in these
studies VAE had been appliedi nc o m p a r a t i v e l yl o w
doses. Studies applying high doses did not explicitly
mention clinical infections, but as they mostly closely
monitored patients for ADRs a potential increase of
infections or infectious complications should have been
noticed. Two pharmacoepidemiologic studies - excluded
here as the applied dosage was not reported - found no
difference in infections and mucositis in VAE-treated
cancer patients compared to the control group
[110,111].
Other functional assessments of the immune system
refer to the humoral and cellular response to foreign
antigens in a variety of animal experiments. They
showed a substantial enhancement of immune response,
even when ML were applied in very high dosages (see
Additional file 3). Differing results in subgroups of two
of the 10 experiments [82-84] are most likely caused by
experimental variation, as the outcome in control
groups varied to a similar amount and as the applied
methodology - the SRBC and PFC assay - is known to
be susceptible to variable results due to subjectivity in
measurement, low automation and limited stability of
SRBC [112,113].
Most studies analysed parameters in the peripheral
blood which allows only indirect conclusions; one study,
however, examined tumour tissue, immunologically a
highly relevant compartment. High dosages of VAE had
been injected intratumourally (up to 42000 ng ML). No
immunosuppressant effects were seen but an increase of
some relevant immune cells [114]. Similar results were
observed in animals, where tumour tissue and immune
organs were analysed repeatedly (see Additional file 3).
In the reviewed studies and experiments, no patholo-
gical laboratory immunosupression was observed.
Decreases were largely within the normal range and
often with parameters whose downs as well as ups could
both be considered favourable: For instance, an explora-
tory study (without a control group to differentiate from
natural course and from influence of cancer disease)
had observed a small decrease of CD3+T-cells expres-
sing CD25 after mitogen (PHA) stimulation ("activated”
T-cells) during 6 month VAE treatment in cancer
patients; this decrease had been more pronounced in
the group with initial higher baseline values, which was
higher than normal controls [75] - a pattern typical for
a mere statistical regression. Here, “downs” as well as
“ups” of the CD3+T-cells expressing CD25 can be clini-
cally interpreted in four directions: 1) spontaneous var-
iation without major clinical relevance (statistical
regression); 2) “normalisation” (towards normal values);
3) “suppression” (CD25+T-cells interpreted as “helper
cells”); 4) “stimulation” ( C D 2 5 + T - c e l l sa sc o n t a i n i n g
CD4+CD25+ T-cells that comprise regulatory T-cells,
which suppress an effective immune response against
tumours [115-117]).
When applying active substances, especially in high
dosages, acute, stress-related changes of immune para-
meters can be observed. In contrast to chronic stress,
which suppresses or disrupts immune functions, this
acute stress often acts as an immunoenhancer. Probably
mediated by glucocorticoid and catecholamine hor-
mones, acute stress significantly changes leukocyte dis-
tribution and trafficking of dendritic cells, macrophages
and lymphocytes in the body. This leads to changes in
the number and composition of leukocytes which can
be seen as a transient increase or decrease of the num-
ber of certain immune cells (e.g. lymphocytes, T-, B-
cells, NK-cells, monocytes, neutrophils) and their func-
tional capacity (proliferation, cytotoxicity, phagocytosis,
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reversed again and can differ in animals and humans
[60].
These short-term changes are also observed after VAE
or ML application, when immune parameters are mea-
sured within hours or days: 6 hours after VAE applica-
tion a decrease of NK- and ADCC activity and of the
numbers of lymphocytes, LGLs and monocytes was
measured, while neutrophils increased. 24 hours later
the cell numbers and activities had normalised or
increased [76,77,118,119]. After application of recombi-
nant ML, a slightly different pattern was observed: a
decrease of splenocytes’ NK-cytotoxicity and of the
number of circulating LGLs was observed 48 hours after
injection, while lymphocytes increased and neutrophils
showed no change [91]. These differences may be influ-
enced by spontaneous or experimental variation but
may also be attributed to the application of recombinant
ML, whose biological and biochemical effects differ
from natural ML due to lack of glycosylation [12,120].
In contrast, after application of VAE and isolated pep-
tides, an increase in NK-cytotoxicity was observed after
2 - 4 days [121].
This review concentrates on VAE and ML (ML I, II
and III). ML are important and biologically active com-
pounds of VAE, but they are not the only relevant com-
pounds (see background section). The other
compounds, however, are less thoroughly investigated,
and little data is available in animals and humans.
ML content of different preparations cannot be com-
pared and can differ also for the same preparation (see
methods section). Therefore, the information presented
here serves only as a rough orientation. Furthermore,
one should bear in mind that there are many further
animal experiments conducted on VAE, ML or VAE
compounds than those presented here (Figure 1); most
of these experiments examine antitumour effects and
should not be missed if an according objective is
addressed; our review, however, focused on immune
outcomes and ADRs and therefore included only a small
part of these experiments.
This review is the first to systematically and compre-
hensively assess all animal and human studies on poten-
tial side effects of therapeutically applied high-dose VAE
or ML. The question arises whether a bias is inherent as
all study designs were included and as several of the
included studies have minor or major methodological
weaknesses. For instance, some of the studies had insuf-
ficiently described methods for detecting adverse effects
or scantily reported the results. This is important as dif-
ferent methods of monitoring for adverse effects yield
different results. For instance, active surveillance yields
higher frequencies than passive, less-formalised methods
[122]. Also reporting, definition, combined reporting or
generic statements influence the results [49]. Still, most
of the clinical studies, and especially all RCTs and all
studies with safety as primary objective had reported
standardised assessment of immune parameters accord-
ing to existing guidelines. Single-arm studies, comparing
immune outcomes with the status before intervention,
have a high risk of bias, i.e. of false positive findings: the
changes often cannot be differentiated from effects of
other factors that influence the immune system and
may induce adverse events; these factors are omnipre-
sent in cancer patients: cancer itself, anticancer treat-
ment, cancer remission, other medications,
complications, infections, etc. We therefore consider
false positive results - i.e. adverse events or immune
“depressions” that were in fact not caused by VAE or
ML - to be highly probable, especially in single-arm stu-
dies. Even when healthy young subjects are asked to
document everyday symptoms for a couple of days, the
occurrence of common unspecific “side effects” have a
similar magnitude as in clinical studies, i.e. fatigue in
41% or headache in 15% [123]. Nevertheless, we have
included studies rather widely. Single-arm studies inves-
tigated higher dosages and alternative routes of applica-
tion, and observational studies better reflect actual
patient care. We did not want to miss potentially rele-
vant risks of VAE treatment and consider it less proble-
matic to overreport unspecific side effects than to miss
a relevant major risk. Altogether, the results are coher-
e n ta n dt h ek i n do fA D R si np r i n c i p l ep l a u s i b l e-
although they might be overrated, especially in studies
without a proper control group.
The studies may have missed ADRs that were too
weak or short to be documented in the studies or linked
to very high dosages. However, as the studies reviewed
h a di n v e s t i g a t e dal a r g er a n g eo fd o s e sa sw e l la sa l l
relevant application forms, as the treatment and screen-
ing periods covered different periods - daily, weekly,
monthly -, and as relevant recommended parameters
had been documented and as patients with different dis-
eases and disease-related or therapy-induced organ dys-
function had been included, we consider the unnoticed
occurrence of major and clinically relevant ADRs to be
highly unlikely. Minor, less relevant or short term effects
or very rare events, however, may have been missed.
In order to minimize publication bias in this review, a
comprehensive search was conducted, unpublished trials
were included and we had long discussions with experts
in the fields. We consider it unlikely that important, rig-
orous trials went unnoticed, at least in Europe. How-
ever, we cannot exclude the possibility that we missed
minor ones, or trials conducted in distant, non-Eur-
opean countries. Furthermore, studies and especially
animal experiments did not report all details on immu-
nological parameters and safety outcomes; we presume
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ify this issue.
In total, VAE seem to exhibit a low risk also in higher
dosages, but, depending on the dosage, dosage change,
application form and individual tolerability, the patient
should be monitored or the treatment directly applied
by the physician. Regarding research, future clinical stu-
dies should follow general recommendations for asses-
sing and reporting harm (e.g. [124]) and adverse event
case reports should take into account corresponding
guidelines for publication (e.g. [125]). Reports on animal
experiments - that only rarely mentioned adverse effects
- should, in the future, include a description of tolerabil-
ity and harm of VAE and its compounds.
Conclusions
In 48 animal experiments and 69 clinical studies investi-
gating higher dosages of VAE, no indications of immu-
nosuppression were found. Quite the opposite, most of
the studies describe a distinct immunostimulation, even
at high dosages of VAE or ML. As the investigations
comprised high doses, relevant treatment and assess-
ment periods and relevant parameters, we consider
clinically relevant immunosuppression to be unlikely.
ADRs observed during higher dose VAE or ML often
consist of LR and FLS, or some non-specific effects, and
allergic or pseudoallergic reactions in some cases, and,
after application of high-dose recombinant ML, of rever-
sible hepatotoxic effects. For normal application VAE is
safe: it can also be presumed to be of low risk when
used for local or systemic high dose application if it is
monitored by an experienced physician.
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